source
- Federal court blocks mailing of mifepristoneLongevity "blue zones," an update on uterine transplant science, and more Morning Rounds health newsSTAT · 4mo ago↗ source
- UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseasesThe buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.BioPharma Dive · 4mo ago↗ source
- What is your AI drug repurposing strategy missing?Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.BioPharma Dive · 4mo ago↗ source